Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinitech LaboratoryBOM:544220 -7.50%38 Piotroski F-Score is 2 as of Aug. 23, 2026, which is 67% below its 10-year median of 6.00. GuruFocus rates BOM:544220 with a GF Score™ of 38/100. The stock has 6 warning signs investors should review. Among 209 Medical Diagnostics & Research companies, Clinitech Laboratory ranks worse than 91.39% on this metric.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Clinitech Laboratory has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Clinitech Laboratory's Piotroski F-Score or its related term are showing as below:
BOM:544220'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 6 Max: 7
Current: 2
During the past 6 years, the highest Piotroski F-Score of Clinitech Laboratory was 7. The lowest was 2. And the median was 6.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Clinitech Laboratory Piotroski F-Score Related Terms
Clinitech Laboratory Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Clinitech Laboratory's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544220 vs TMO, DHR, IDXX: Piotroski F-Score Comparison
For the Diagnostics & Research subindustry, Clinitech Laboratory's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinitech Laboratory Piotroski F-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinitech Laboratory's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Clinitech Laboratory's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Clinitech Laboratory's current Net Income (TTM) was 4.15.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Clinitech Laboratory's return on assets of this year was 0.03872112. Clinitech Laboratory's return on assets of last year was 0.0703816.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Clinitech Laboratory's gearing of this year was 0.04910649. Clinitech Laboratory's gearing of last year was 0.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Clinitech Laboratory's current ratio of this year was 6.49973559. Clinitech Laboratory's current ratio of last year was 4.35951051.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Clinitech Laboratory's number of shares in issue this year was 2.267. Clinitech Laboratory's number of shares in issue last year was 2.077.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Clinitech Laboratory's gross margin of this year was 0.7283589. Clinitech Laboratory's gross margin of last year was 0.77745935.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Clinitech Laboratory's asset turnover of this year was 0.885993. Clinitech Laboratory's asset turnover of last year was 1.46842011.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
0
+
0
+
0
+
0
+
1
+
0
+
0
+
0
=
2
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Clinitech Laboratory has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
Clinitech Laboratory (BOM:544220) has a Piotroski F-Score of 2 as of Aug. 23, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Clinitech Laboratory and its competitors. This is 67% below median its historical median of 6.00. Over the past decade, Clinitech Laboratory's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Clinitech Laboratory ranks #191 out of 209 companies in the Medical Diagnostics & Research industry, placing it in the top 91.4%.
Is Clinitech Laboratory's Piotroski F-Score too high?
Clinitech Laboratory's current Piotroski F-Score of 2 is 67% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Clinitech Laboratory's value of 2 is 60% below this industry median. Based on the distribution chart, Clinitech Laboratory ranks #191 out of 209 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Clinitech Laboratory has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Clinitech Laboratory's Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinitech Laboratory ranks #191 out of 209 companies for Piotroski F-Score. This places Clinitech Laboratory in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Clinitech Laboratory's value of 2 is 60% below this benchmark. Historically, Clinitech Laboratory's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Clinitech Laboratory has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 209 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinitech Laboratory's current Piotroski F-Score of 2 is 60% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Clinitech Laboratory and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinitech Laboratory's current Piotroski F-Score is 2, which is 67% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinitech Laboratory stock overvalued right now?
Clinitech Laboratory (BOM:544220) has a current Piotroski F-Score of 2. The current Piotroski F-Score is 2, which is 67% below median its 10-year median of 6.00 and 60% below the Medical Diagnostics & Research industry median of 5.00. Clinitech Laboratory's overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Clinitech Laboratory (BOM:544220), the current Piotroski F-Score is 2 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clinitech Laboratory Ltd is an Indian diagnostic and healthcare services provider company. It operates a network of diagnostic centers in Thane and Navi Mumbai and offers various medical tests across multiple specialties, including biochemistry, immunology, hematology, molecular biology, serology, microbiology, and histopathology. It serves individual patients as well as corporate clients, aiming to provide affordable and comprehensive diagnostic solutions.
38GF Score
Get the complete analysis for BOM:544220
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544220 has been successfully added to your 
